NTRA, US6323071042

Natera stock sets 2029 revenue target above 6 billion US dollars

Published on 11/19/2026 at 14:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Natera stock enters a broader growth phase built around Signatera and reimbursement gains. A CEO transition adds an execution focus.

Growth plan widens beyond cancer testing

  • Management sees Signatera as the main engine of expansion, supported by reimbursement gains and higher average selling prices.
  • The FIND-CRC colorectal cancer screening study is expected to report in 2027 and could broaden Natera's addressable market.
  • A planned CEO transition keeps execution and clinical development at the center of the investment case.
NTRA, US6323071042, Illustration mit AI erstellt.

Natera outlined a wider growth plan at the Jefferies Global Healthcare Conference on Wednesday, November 18, according to Investing.com. Chief Financial Officer Mike Brophy said the company is targeting more than 6 billion US dollars in revenue by 2029, with Signatera remaining the main growth engine.

Natera stock traded at 268.70 euros on Lang & Schwarz at 14:01 CET on Thursday, November 19. The quote was dated to the publication day and stood without a verified Xetra comparison.

Signatera remains the central growth engine

Brophy said revenue grew 42 percent year over year excluding revenue true-ups, while full-year 2026 revenue guidance is now above 3 billion US dollars. The conference discussion described Signatera as a roughly 20 billion US dollar annual opportunity, with Natera having reached about 1 billion US dollars of that market so far.

Management said the test's average selling price is about 1,290 US dollars and outlined a path toward 1,450 US dollars by 2029. The proposed increase depends on broader reimbursement, including further Medicare Advantage compliance, commercial payer coverage in states with relevant mandates and possible inclusion in clinical practice guidelines.

Natera has nine additional MolDX coverage applications in progress, according to the conference discussion. Brophy said decisions typically take nine to 12 months. Liver cancer coverage was received shortly before the third-quarter earnings call, adding one recent reimbursement milestone to the expansion plan.

Clinical pipeline adds longer-term optionality

The company also highlighted Signatera Genome, which uses whole-genome sequencing and phased and structural variants technology. Management said the newer approach can broaden the variant menu and improve sensitivity, while higher production costs should normalize over a couple of quarters.

Several prospective outcomes trials are expected to report in 2027 and 2028. Natera also expects the FIND-CRC study, a colorectal cancer screening trial enrolling more than 25,000 patients, to report in 2027. Management said a successful result could expand the addressable market beyond the current Signatera opportunity.

Pharma services were another focus. Natera said the IMvigor010 result, in which Signatera was used to select patients for a bladder cancer study, helped increase pharmaceutical partnerships and contracted value. The company presented the business as a way to support more efficient clinical-trial design.

Leadership change raises execution focus

Steve Bianchi is stepping down as chief executive after eight years in the role, with Solomon Moshkevich set to take over. The company described the handover as orderly and emphasized Moshkevich's long involvement with Prospera and Signatera.

For investors, the plan combines rapid testing growth with substantial execution requirements. Reimbursement decisions, clinical readouts and the transition to the new chief executive will shape how quickly Natera can convert its expanding opportunity into revenue and improved profitability.

Natera at a glance

  • Company: Natera, Inc.
  • ISIN: US6323071042
  • Ticker: NTRA
  • Trading venue: Lang & Schwarz
  • Quote: 268.70 euros at 14:01 CET on November 19, 2026

US equities traded in a broader market environment represented by the S&P 500.

More news and analyses on Natera stock

Disclaimer...
en | US6323071042 | NTRA | boerse | 70536152 | bgmi